Lyra Therapeutics Inc LYRA Stock Analysis
- OTCMKTS
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.19 unchanged at close Nov 6
Last close · Previous close $0.19
- Market cap
- $312.45KAt the Nov 6 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$0.19unchangedPast month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.19Nov 5
- Volume90.00Nov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume945.00Last 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.00 to $4.80; now $0.19
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
LYRA beat the S&P 500 in 1 of 6 periods.
| Period | LYRA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | LYRA: unchanged S&P 500: down 5.6% | LYRA beat the S&P 500 by 5.6 percentage points Beat |
| 3M | LYRA: down 52.5% S&P 500: down 4.1% | LYRA trailed the S&P 500 by 48.4 percentage points Trailed |
| YTD | LYRA: down 93.8% S&P 500: up 8.7% | LYRA trailed the S&P 500 by 102.5 percentage points Trailed |
| 1Y | LYRA: down 96.1% S&P 500: up 10.9% | LYRA trailed the S&P 500 by 107.0 percentage points Trailed |
| Long term | ||
| 3Y | LYRA: down 99.9% S&P 500: up 75.0% −89.1% vs +20.5% a year | LYRA trailed the S&P 500 by 174.9 percentage points Trailed |
| 5Y | LYRA: down 99.9% S&P 500: up 67.8% −77.6% vs +10.9% a year | LYRA trailed the S&P 500 by 167.7 percentage points Trailed |
$10,000 invested in LYRA 5 years ago (Nov 5, 2021) would be worth about $6 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
LYRA beat the S&P 500 in 1 of 6 periods.
| Period | LYRA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | LYRA: unchanged S&P 500: down 5.6% | LYRA beat the S&P 500 by 5.6 percentage points Beat |
| 3M | LYRA: down 52.5% S&P 500: down 4.3% | LYRA trailed the S&P 500 by 48.2 percentage points Trailed |
| YTD | LYRA: down 93.8% S&P 500: up 7.8% | LYRA trailed the S&P 500 by 101.6 percentage points Trailed |
| 1Y | LYRA: down 96.1% S&P 500: up 9.7% | LYRA trailed the S&P 500 by 105.8 percentage points Trailed |
| Long term | ||
| 3Y | LYRA: down 99.9% S&P 500: up 68.8% −89.1% vs +19.1% a year | LYRA trailed the S&P 500 by 168.7 percentage points Trailed |
| 5Y | LYRA: down 99.9% S&P 500: up 56.9% −77.6% vs +9.4% a year | LYRA trailed the S&P 500 by 156.8 percentage points Trailed |
$10,000 invested in LYRA 5 years ago (Nov 5, 2021) would be worth about $6 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$928.00
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since May 1, 2020.
Stock splits
1
1-for-50 on . Share counts adjust after each split.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Sep 30, 2025). Tap a metric to see how it’s calculated. Per-share results and the measures based on them are paused. See the note under the price.
Price-to-earnings (P/E)
Paused
Other valuation measures
- 0.5×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - Price-to-bookPausedBook value as of Sep 30, 2025
See the note under the price. - PEG ratioPausedLast 12 months’ EPS growth
See the note under the price. - −10,910.37%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $7.64MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Sep 30, 2025 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own LYRA DCF in Excel. Value Lyra Therapeutics with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY25, the quarter ended Sep 30, 2025. “Last 12 months” means the four quarters from Oct 1, 2024 to Sep 30, 2025, and balance-sheet figures are as of Sep 30, 2025.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $600.00Kdown 59.2%
- Net income
- −$32.95M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY23 (Dec 31, 2023) | $146.00K | −$15.16M | Paused See the note under the price. |
| Q1 FY24 (Mar 31, 2024) | $532.00K | −$22.45M | Paused See the note under the price. |
| Q2 FY24 (Jun 30, 2024) | $598.00K | −$48.13M | Paused See the note under the price. |
| Q3 FY24 (Sep 30, 2024) | $195.00K | −$11.87M | Paused See the note under the price. |
| Q4 FY24 (Dec 31, 2024) | $209.00K | −$10.98M | Paused See the note under the price. |
| Q1 FY25 (Mar 31, 2025) | $183.00K | −$8.55M | Paused See the note under the price. |
| Q2 FY25 (Jun 30, 2025) | $183.00K | −$7.44M | Paused See the note under the price. |
| Q3 FY25 (Sep 30, 2025) | $25.00K | −$5.98M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY20 (Dec 31, 2020) | $0.00 | −$22.13M | Paused See the note under the price. |
| FY21 (Dec 31, 2021) | $285.00K | −$43.51M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $1.36M | −$55.28M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $1.56M | −$62.68M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $1.53M | −$93.44M | Paused See the note under the price. |
Margins
- Gross 100.0%
- Operating −5,885.3%
- Net −5,491.2%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$34.09MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$34.15MLast 12 months
- Capital spending$56.00KLast 12 months
- −5,681.5%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $5.00MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $24.05MAs of Sep 30, 2025
Cash plus short- and long-term marketable securities on the Sep 30, 2025 balance sheet.
- Total debt$31.38MAs of Sep 30, 2025
- Net debt$7.33MAs of Sep 30, 2025
- Book value per sharePausedAs of Sep 30, 2025
See the note under the price. - 2.43As of Sep 30, 2025
Current assets divided by current liabilities on the Sep 30, 2025 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
- 1 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✓Return on assets improved: passed
- ✗Operating cash flow exceeded net income: not passed
- ✗Long-term debt fell relative to assets: not passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −1,032.8%Last 12 months
Over the last 12 months, Lyra Therapeutics lost money: its net loss was 1,032.8% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −60.2%Last 12 months
Over the last 12 months, Lyra Therapeutics’s net loss was 60.2% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Lyra Therapeutics Inc
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company’s proprietary technology platform, XTreo™, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS). The therapeutic embedded within LYR-210 and LYR-220 is mometasone furoate, which is the active ingredient in various FDA-approved drugs and has a well-established efficacy and safety profile. CRS is an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities and affects approximately 14 million people in the United States. The company is advancing LYR-210 as a potential preferred alternative to surgery in an ongoing Phase 2 clinical trial for CRS patients who have failed medical management. In its Phase 1 clinical trial, LYR-210 met its primary safety endpoint, and it was observed that patients generally experienced significant and rapid, clinically meaningful and durable improvement in SNOT-22 scores, an established patient symptom severity scale, through week 25, which was the end of the trial. The company is also developing LYR-220 for use in CRS patients who have an enlarged nasal cavity due to sinus surgery but continue to require treatment to manage CRS symptoms. Beyond CRS, the company believes its XTreo platform has potential applications in other disease areas, which it is actively exploring to further broaden the platform’s therapeutic potential.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Massachusetts, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- OTCMKTS
- Asset type
- Common stock
- Price history since
LYRA news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
LYRA stock FAQ
What is LYRA stock’s price today?
Lyra Therapeutics (LYRA) traded at $0.19 at the close on , unchanged from the previous close of $0.19. Over the past 52 weeks it has traded between $0.00 and $4.80.
If you invested $1,000 in LYRA 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in LYRA on would be worth about $1 at the close on , a total return of −99.9%. The same $1,000 would be worth $39 if invested one year ago. Past performance doesn’t predict future returns.
What is Lyra Therapeutics’s market cap?
Lyra Therapeutics’s market capitalization is about $312.4 thousand. That’s Tiingo’s daily market cap for , at that day’s closing price of $0.19 (how market cap works).
How much revenue does Lyra Therapeutics make?
Lyra Therapeutics reported $600.0 thousand of revenue over the four quarters to , down 59.2% from the twelve months before. In its latest quarter (Q3 FY25, ended ) revenue was $25.0 thousand, down 87.2% from a year earlier.
Is Lyra Therapeutics profitable?
Not over the four quarters to . Lyra Therapeutics reported a net loss of $32.9 million across those four quarters on $600.0 thousand of revenue.
Does LYRA pay a dividend?
Lyra Therapeutics hasn’t paid a dividend in the last twelve months.
What is LYRA’s 52-week high and low?
Over the past 52 weeks LYRA has traded as low as $0.00 and as high as $4.80. At $0.19 at the close on , it is 96.0% below that high and 47,400.0% above the low.
What is LYRA’s all-time high?
LYRA’s highest closing price was $928.00 on , adjusted for stock splits. At $0.19 at the close on , it is 100.0% below that record.
Has LYRA stock ever split?
Yes, once: 1-for-50 on .
How has LYRA stock performed?
Including dividends and measured to the close on , LYRA has returned −93.8% so far this year and −96.1% over the past year, and −99.9% over five years (−77.6% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Lyra Therapeutics in?
Lyra Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in Massachusetts, USA.
What exchange does LYRA trade on?
Lyra Therapeutics trades on the OTCMKTS under the ticker symbol LYRA. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.